Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors

• Главные авторы: Yuchun Niu (Автор), Anqi Lin (Автор), Peng Luo (Автор), Weiliang Zhu (Автор), Ting Wei (Автор), Ruixiang Tang (Автор), Linlang Guo (Автор), Jian Zhang (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2020-08-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

BackgroundImmune checkpoint inhibitors (ICIs) are an important treatment modality that must be considered for patients with lung adenocarcinoma (LUAD). However, ICIs are effective only in some of these patients. Therefore, identifying biomarkers that accurately predict the prognosis of patients with...